RedHill Biopharma Ltd. announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes' U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment.

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

The findings suggest that the antiviral can prevent over 90% of viral replication if given at the optimal time, the authors say.

Data: Optimal initiation of Paxlovid in hospitalized COVID patients is 3 to 5 days

First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat)1 for early COVID-19 outpatient treatment, funded through non-dilutive external sources, including the U.S. Department of Defense.

Researchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit from the treatment, according to a study published April 16 in eLife.

Optimal timing maximizes Paxlovid benefits for treating COVID-19

MSD said on April 16 that it has filed a smaller easier-to-swallow tablet version of its oral COVID-19 treatment Lagevrio (molnupiravir) in Japan.

Lagevrio’s Smaller Tablet Version Filed in Japan: MSD

Use of the antiviral was linked to a significant decline in in-hospital death at both 14 and 28 days, regardless of variant of concern.

antiviral news

Press Releases in the global landscape